Novo Nordisk A/S (NVO) is a Healthcare · Drug Manufacturers - General company listed on NYSE. Price $43.24 (+0.12%), Market cap $198.26B, P/E ratio 10.38, 52-week low–high $35.29 ~ $81.05.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada
Financial statements, price targets, institutional (13F) holdings and related news for Novo Nordisk A/S are updated in real time on BlackAll Trade.
4 recent posts · 4 bullish · 0 bearish · 0 neutral.
Novo Nordisk A/S trades at $43.24 (+0.12%). Real-time quotes and charts are available on BlackAll Trade.
Novo Nordisk A/S has a market cap of about $198.26B. Its P/E ratio is 10.38.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabe